AlphaCentric Advisors’s Fusion Pharmaceuticals FUSN Stock Holding History
Bought
Maintained
Sold
Other funds holding FUSN
AlphaCentric Advisors's FUSN Position: Q4 2021 in Review
AlphaCentric Advisors increased its Fusion Pharmaceuticals (FUSN) stake by 40% in Q4 2021, buying an estimated $178K and bringing the position to 100,000 shares worth $417K. The position accounts for 0.12% of the portfolio, ranked #68.
AlphaCentric Advisors first reported a position in FUSN in Q2 2020 and has held it in 7 quarters since. The position peaked at $578K in Q2 2021. 32 funds tracked by Wall St. Rank hold FUSN as of Q4 2021.
- AlphaCentric Advisors held 100,000 shares of Fusion Pharmaceuticals worth $417K as of Q4 2021.
- AlphaCentric Advisors bought 28,500 Fusion Pharmaceuticals shares in Q4 2021, an estimated $178K.
- Fusion Pharmaceuticals made up 0.12% of AlphaCentric Advisors's portfolio in Q4 2021, its #68 holding.
- AlphaCentric Advisors first reported a position in Fusion Pharmaceuticals in Q2 2020 and has held it in 7 quarters since.
- AlphaCentric Advisors's Fusion Pharmaceuticals position peaked at $578K in Q2 2021.
- 32 funds tracked by Wall St. Rank held Fusion Pharmaceuticals as of Q4 2021.
Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.